Objective To observe the efficacy and toxicity of combination regimen contains lobaplatin in treatment of advanced metastatic breast cancer. Methods From January 2010 to May 2012,47 patients with advanced metastatic breast cancer were enrolled in this study. Lobaplatin ( 30mg/m2 ) combined with another chemotherapeutic agents were given to patients. Twenty-bne to twenty-eight days was a cycle. The efficacy and side effects were evaluated after at least two cycles of chemotherapy. Results Therapeutic efficacy and adverse reactions could be evaluated in all patients with no CR patient, 13 cases of PR,22 cases of SD and 12 cases of PD. The response rate ( RR) was 27. 7% and the disease control rate ( DCR) was 74. 5%. Stratification analysis by ER, HER-2 status or second-line and third/more than third-line chemotherapy, no significant differences were found between the DCR and RR. Thirty-six patients had progressed at the deadline of follow-up. The median time to progression was 4. 7 months(95%CI:4. 1-5.3 months). The main side effects were myelosuppression, fatigue and gastrointestinal reaction, which were mosty in grade 1 -2 and alleviated by symptomatic treatment. Conclusion Combination regimen contains lobaplatin for advanced metastatic breast cancer patients is effective and well tolerated.%目的 观察含洛铂的联合化疗方案治疗晚期复治乳腺癌的疗效及毒副反应.方法 收集2010年1月至2012年5月47例治疗后进展的晚期乳腺癌患者,给予含洛铂(30mg/m2)的联合化疗方案,3～4周为1个周期.至少化疗2个周期后评价疗效及毒副反应.结果 全组47例患者均可评价疗效和毒副反应.无1例获CR,PR 13例,SD 22例,PD 12例,有效率(RR)为27.7％,疾病控制率(DCR)为74.5％.ER或HER-2阳性表达者与其阴性表达者DCR比较,差异均无统计学意义(P＞0.05).二线治疗者与三线及以上治疗者的RR比较,差异亦无统计学意义(P＞0.05).至随访截止日期,36例疾病进展,中位疾病进展时间(TTP)为4.7个月(95％CI:4.1～5.3个月).主要毒副反应为骨髓抑制、消化道反应及疲乏等,多为1、2级,经对症处理后均能缓解,无治疗相关性死亡.结论 含洛铂的联合方案治疗晚期复治乳腺癌疗效较好,毒副反应可耐受.
展开▼
